These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 31713012)

  • 1. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality.
    Brouwers MCGJ; Simons N; Stehouwer CDA; Isaacs A
    Diabetologia; 2020 Feb; 63(2):253-260. PubMed ID: 31713012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N; Häring HU; Cusi K
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population.
    Wang X; Liu Z; Wang K; Wang Z; Sun X; Zhong L; Deng G; Song G; Sun B; Peng Z; Liu W
    Front Genet; 2016; 7():140. PubMed ID: 27532011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of NASH.
    Armandi A; Bugianesi E
    Liver Int; 2021 Jun; 41 Suppl 1(Suppl 1):78-82. PubMed ID: 34155792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease and risk of type 2 diabetes.
    Lallukka S; Yki-Järvinen H
    Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):385-95. PubMed ID: 27432073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease.
    Brouwers MCGJ; Simons N; Stehouwer CDA; Koek GH; Schaper NC; Isaacs A
    Hepatol Commun; 2019 Apr; 3(4):587-596. PubMed ID: 30976747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.